Discontinuation Rates of Anticholinergic Medications Used for the Treatment of Lower Urinary Tract Symptoms
about
Real life persistence rate with antimuscarinic treatment in patients with idiopathic or neurogenic overactive bladder: a prospective cohort study with solifenacin.Urgency urinary incontinence in women 50 years or older: incidence, remission, and predictors of change.Tolterodine extended-release for overactive bladder.OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder.A group-based yoga therapy intervention for urinary incontinence in women: a pilot randomized trialA current perspective on geriatric lower urinary tract dysfunction.Validation of a self-administered instrument to measure adherence to anticholinergic drugs in women with overactive bladder.Percutaneous tibial nerve stimulation: a clinically and cost effective addition to the overactive bladder algorithm of care.Diagnosis and office-based treatment of urinary incontinence in adults. Part two: treatment.Vitamin D and incident urinary incontinence in older adults.Update on tolterodine extended-release for treatment of overactive bladderTreatment compliance of working persons to high-dose antimuscarinic therapies: a randomized trialLong-term adherence to antimuscarinic drugs when treating overactive bladder in the older: Subjective reason and objective factors.Combination of foot stimulation and tolterodine treatment eliminates bladder overactivity in cats.Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature.Treatment of overactive bladder symptoms beyond antimuscarinics: current and future therapies.What are the barriers and how do we manage them? A review of progress over the last 10 years.Intradetrusor onabotulinumtoxinA for overactive bladder.Chapter 1: The conditions of neurogenic detrusor overactivity and overactive bladder.Percutaneous tibial nerve stimulation and sacral neuromodulation: an update.The role of acupuncture in managing overactive bladder; a review of the literature.Self-assessment of treatment compliance with antimuscarinic drugs and lower urinary tract condition among women with urinary incontinence.The effective tool for self-assessment of adherence to treatment in patients with benign prostatic obstruction and overactive bladder symptoms.Limitations of anticholinergic cycling in patients with overactive bladder (OAB) with urinary incontinence (UI): results from the CONsequences of Treatment Refractory Overactive bLadder (CONTROL) study.InterStim Therapy: A Contemporary Approach to Overactive Bladder.Impact of onabotulinumtoxinA on quality of life and practical aspects of daily living: A pooled analysis of two randomized controlled trials.Persistence with first line anticholinergic medication in treatment-naïve overactive bladder patients.Long-term safety and efficacy of two different antimuscarinics, imidafenacin and solifenacin, for treatment of overactive bladder: a prospective randomized controlled study.Augmentation enterocystoplasty in overactive bladder: is there still a role?Epidemiology and healthcare utilization of neurogenic bladder patients in a US claims database.A new tool for self-evaluation of adherence to antimuscarinic drugs treatment in patients with urinary incontinence.Comparison of objective and subjective factors in the adherence to antimuscarinics when treating overactive bladder in employed persons.Phase III Study to Assess Long-Term (52-Week) Safety and Efficacy of Mirabegron, a β3 -Adrenoceptor Agonist, in Japanese Patients with Overactive Bladder.Sustained therapeutic effects of percutaneous tibial nerve stimulation: 24-month results of the STEP study.Effectiveness of a new tool for self-evaluation of adherence to antimuscarinic drug treatment in older patients of both sexes with urge incontinence.Efficacy and Safety of the Selective β3 -Adrenoceptor Agonist Mirabegron in Japanese Patients with Overactive Bladder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study.Medical Record DatabasesPatterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United Kingdom
P2860
Q33560320-84D625C6-2890-4F00-BE1E-A802C5DCDA8EQ34591469-A470858E-AC34-4323-9303-21C06BD5443BQ34610640-7A1C228B-FB17-4A9B-8D16-5BBC298EAD20Q34804892-37F4FB14-37A6-4C33-B4D0-71E22F6E6406Q35026842-E3F4A531-2F0A-4AC8-981E-526AB39362BAQ35348864-BA93494C-5E47-4F95-B1E4-78F41255EA2FQ35572326-44B992E4-0AD2-46B1-A059-C3ABA32C5E3EQ36223634-DFC0E40B-1104-42F3-AC75-A59270335844Q37040776-284EBAB3-0969-4E53-93EE-9454C05838CCQ37239126-C1FBABCE-6F15-4323-ACB9-9DA52BFFF50EQ37283585-A969AA9A-A5F7-4ED8-8165-2B0B3A25C800Q37461417-BF7260BE-3416-468C-B983-FF949A2FD6B6Q37671696-D45AA144-1FD1-4473-8A35-0569F20923C2Q37728633-A59B385D-2EE4-480E-B976-68FBEA498F29Q37864717-13F9D32C-2639-4386-A6BF-DC73049981A1Q38018206-E239DDFB-50DF-468B-9598-14294E152956Q38187655-0B20AB54-C215-486B-A3C2-12A249DEA0A0Q38198733-CD4BBB21-F9DC-4379-9188-6354DB8FFAE5Q38231743-43BFB31B-BD90-4FC7-A2DD-D792E954B0D9Q38335861-29A361D8-A0F6-4B12-9BCA-17F671038560Q38689041-5E236F41-1A14-4A9D-8E4A-816B946C8FBCQ38827514-9257CB19-7171-4AB2-87D3-1565CA167CF6Q39027722-45A3B333-2789-4CB7-8D49-EA9281EAA29FQ39874458-4C14B41D-54A5-4794-858C-3A59EBED777BQ39984273-CB6EACB1-E0A9-4B7B-8917-A9073D23067AQ40989355-22D29A77-F6F7-4216-9161-2D0299E5B9B5Q46113025-B428735A-FF59-4D2C-80CE-DA7F20130D9DQ46351979-F6C6FEC3-F1F9-4AA0-A30F-0B1C12F81767Q46478368-C21E2A36-3E1E-4E49-8509-416967B8AC6FQ46560975-F269E46D-F9BA-411F-A46D-9F68A00B7931Q47172054-1604B340-F1DA-46B6-9282-5B98A03D5D48Q47546972-E8B55304-260C-4E9B-BDE2-569D5F003150Q47585163-BAF73B76-AEE8-46FC-9EB9-3FB26DD2FF1EQ47655067-641588D6-175D-4846-A28D-EEAD6637FA98Q47690070-B2AFA4D0-5D4F-4D59-B805-39F378575E17Q51607907-804C927E-F762-4FA8-A839-52A07620FA0FQ57299690-0D5DA35D-EC5A-4EE7-AA76-FC2EB133C1B7Q57608703-EF5F9D63-8EF7-4A7E-BF21-D3A8D48370DC
P2860
Discontinuation Rates of Anticholinergic Medications Used for the Treatment of Lower Urinary Tract Symptoms
description
2008 nî lūn-bûn
@nan
2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Discontinuation Rates of Antic ...... f Lower Urinary Tract Symptoms
@ast
Discontinuation Rates of Antic ...... f Lower Urinary Tract Symptoms
@en
type
label
Discontinuation Rates of Antic ...... f Lower Urinary Tract Symptoms
@ast
Discontinuation Rates of Antic ...... f Lower Urinary Tract Symptoms
@en
prefLabel
Discontinuation Rates of Antic ...... f Lower Urinary Tract Symptoms
@ast
Discontinuation Rates of Antic ...... f Lower Urinary Tract Symptoms
@en
P2093
P1476
Discontinuation Rates of Antic ...... f Lower Urinary Tract Symptoms
@en
P2093
Kevin Haynes
Lily A. Arya
Manish Gopal
Scarlett L. Bellamy
P304
P356
10.1097/AOG.0B013E31818E8AA4
P407
P577
2008-12-01T00:00:00Z